Overview A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051) Status: Completed Trial end date: 2016-05-25 Target enrollment: Participant gender: Summary This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine. Phase: Phase 1 Details Lead Sponsor: Merck Sharp & Dohme Corp.